Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma

被引:18
|
作者
Huang, Jing Li [1 ]
Kizy, Scott [1 ]
Marmor, Schelomo [1 ]
Altman, Ariella [1 ]
Blaes, Anne [2 ]
Beckwith, Heather [2 ]
Tuttle, Todd M. [1 ]
Hui, Jane Yuet Ching [1 ]
机构
[1] Univ Minnesota, Dept Surg, Mayo Mail Code 195,420 Delaware St SE, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Mayo Mail Code 480,420 Delaware St SE, Minneapolis, MN 55455 USA
关键词
Breast cancer; 21-Gene recurrence score; Oncotype DX; Grade; Progesterone receptor; ENDOCRINE THERAPY; HISTOLOGIC GRADE; GENE-EXPRESSION; CANCER PATIENTS; ASSAY; ESTROGEN; IMPACT; CHEMOTHERAPY; VALIDATION; EQUATIONS;
D O I
10.1007/s10549-018-4955-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization.MethodsWe identified women between the ages of 18 and 74years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS.ResultsWe identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31-0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15-0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+tumors regardless of age, race, tumor size, and lymph node status.ConclusionsWe found that grade I PR+tumors are associated a<5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
引用
收藏
页码:671 / 677
页数:7
相关论文
共 50 条
  • [41] The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment
    Josee-Lyne Ethier
    Eitan Amir
    Molecular Diagnosis & Therapy, 2016, 20 : 307 - 313
  • [42] The 21-gene recurrence score and effects of adjuvant radiotherapy after breast conserving surgery in early-stage breast cancer
    Dong, Yong
    Zhang, Wen-Wen
    Wang, Jun
    Sun, Jia-Yuan
    He, Zhen-Yu
    Wu, San-Gang
    FUTURE ONCOLOGY, 2019, 15 (14) : 1629 - 1639
  • [43] Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21-Gene Recurrence Score
    Kamal, Arif H.
    Loprinzi, Charles L.
    Reynolds, Carol
    Dueck, Amylou C.
    Geiger, Xochiquetzal J.
    Ingle, James N.
    Carlson, Robert W.
    Hobday, Timothy J.
    Winer, Eric P.
    Goetz, Matthew P.
    ONCOLOGIST, 2011, 16 (10): : 1359 - 1366
  • [44] 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer
    Chen, Xiang-Hong
    Zhang, Wen-Wen
    Wang, Jun
    Sun, Jia-Yuan
    Li, Feng-Yan
    He, Zhen-Yu
    Wu, San-Gang
    BIOMARKERS IN MEDICINE, 2019, 13 (02) : 83 - 93
  • [45] Correlation between anthropometric pathologic data, and 21-gene recurrence score assay in early-stage breast cancer
    Quintyne, Keith Ian
    Woulfe, Bernie
    Coate, Linda
    Gupta, Rajnish K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] The 21-Gene Recurrence Score Adds Significant Prognostic and Predictive Value for Grade 3 Breast Carcinomas
    Iorgulescu, J. Bryan
    Lester, Susan
    Brock, Jane
    LABORATORY INVESTIGATION, 2018, 98 : 75 - 76
  • [47] Clinicopathological predictors for low risk recurrence distinguished by 21-gene recurrence score in estrogen receptor-positive invasive breast cancer patients
    Tsuchida, Y.
    Hayashi, N.
    Omata, F.
    Yamauchi, H.
    CANCER RESEARCH, 2017, 77
  • [48] The 21-Gene Recurrence Score Adds Significant Prognostic and Predictive Value for Grade 3 Breast Carcinomas
    Iorgulescu, J. Bryan
    Lester, Susan
    Brock, Jane
    MODERN PATHOLOGY, 2018, 31 : 75 - 76
  • [49] Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage
    Yang Yu-qing
    Wang Lei
    Huang Mei-ling
    Xiao Jing-jing
    Wei Mei-chen
    Wu Jiang
    Hao Jun-sheng
    Ling Rui
    Li Nan-lin
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2019, 108 : 150 - 155
  • [50] BREAST CANCER The 21-gene recurrence score - biology remains at the forefront
    Puhalla, Shannon L.
    Davidson, Nancy E.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 470 - 472